Clinical Trial Detail

NCT ID NCT02429193
Title Biomarkers of Androgen Response and Resistance In Evolution During a Rising PSA (BARRIER-P)
Recruitment Completed
Gender male
Phase Phase II
Variant Requirements No
Sponsors University Health Network, Toronto
Indications

prostate cancer

Therapies

Enzalutamide

Abiraterone + Prednisone

Age Groups: adult

No variant requirements are available.